Women who received the HPV vaccine after surgical excision for high-grade cervical dysplasia had lower risk for recurrence than women who received placebo or surgery alone, according to results of a ...
- Data show that Vaxart’s HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related ...
PLYMOUTH MEETING, Pa., Dec. 9, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from ...
Cervical dysplasia is the presence of abnormal cells in the cervix. Cases are classified as mild, moderate or severe depending on the extent of abnormal cell growth. Although the precise cause of ...
Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management Females ≥ 15 years old who received the QHPV vaccine in Manitoba between September ...
This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Mild cellular changes detected by Pap smears don’t necessarily lead to ...
Management of cervical intraepithelial neoplasms depends on the extent of involvement and the histologic appearance of the lesion. A significant number of CIN 1 lesions resolve spontaneously, and no ...
PLYMOUTH MEETING, Pa., Aug. 19, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial ...
PLYMOUTH MEETING, Pa., March 30, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ: INO) today reported interim results from an open-label Phase 2 trial designed to evaluate the safety and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback